Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma - 12/11/11
, Takeshi Nakahara, MD, PhD a, Sayaka Hayashida, MD a, Makiko Kido, MD, PhD a, Lining Xie, MD, PhD a, Masakazu Takahara, MD, PhD a, Hiroshi Uchi, MD, PhD a, Shogo Miyazaki, PhD b, Takeru Abe, MA b, Akihito Hagihara, DMSc, MPH b, Yoichi Moroi, MD, PhD a, Masutaka Furue, MD, PhD a
Reprint requests: Junna Oba, MD, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.Abstract |
Background |
CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified.
Objective |
We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis.
Methods |
A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model.
Results |
Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P < .01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor.
Limitations |
The major limitation was the small sample size.
Conclusion |
CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.
Le texte complet de cet article est disponible en PDF.Key words : Breslow thickness, CD10, immunohistochemistry, malignant melanoma, melanoma-specific survival, prognosis, tumor progression
Abbreviations used : ALM, MM, TIL
Plan
| Supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology; the Ministry of Health, Labour, and Welfare; and the government to the National Cancer Center (21S-7-6), Japan. |
|
| Conflicts of interest: None declared. |
Vol 65 - N° 6
P. 1152-1160 - décembre 2011 Retour au numéro
Article précédent
- Supplement use and risk of cutaneous squamous cell carcinoma
- Maryam M. Asgari, Mary-Margaret Chren, E. Margaret Warton, Gary D. Friedman, Emily White
- Papular and annular fixed urticarial eruption: A characteristic skin manifestation in patients with relapsing polychondritis
- Anne-Fleur Tronquoy, Julie de Quatrebarbes, Damien Picard, Philippe Courville, Xavier Balguerie, Marie Claude Boullie, Fabienne Leonard, Philippe Bernard, Pascal Joly
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?